Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of SKI-O-703 in Healthy Volunteers
NCT03315494Phase 1Completed
- Sponsor
- Oscotec Inc.
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cevidoplenib in rheumatoid arthritis (RA) (4 arms), sponsored by Oscotec Inc. Primary endpoint: Number of participants with reported adverse events at 21 days. Started Sep 2016; status: completed.
02
Drugs
cevidoplenib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03315494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315494.